TGTXTG Therapeutics, Inc.
$55.37+71% 1Y
$55.37
$26.9452 weeks$58.12
TGTX in its own filings
TGTX's filing record carries 3 kinds of hard flag, each is shown beside the share of the whole market carrying the same one, because more than half of all companies carry at least one.
433
Events found in the filings · across 1,148 filings · the record starts in 1996
- Hard flags
- 3
Hard flags
- Most recent filing
- Aug 5, 2026
Most recent filing · Form 10-Q
- Record starts
- Jul 3, 1996
Record starts · the earliest filing Ryufin holds for this name
Details›
- Next results filingsame week as a year ago
- expected around Nov 2, 2026
- Restatement admitted (non-reliance)historical
- 2006-08-14
- Change in certifying accountanthistorical
- 2021-04-13
- Late periodic report12 occurrences
- 2010-05-17
- Delisting notice / listing-rule failure3 occurrences
- 2007-09-21
- Security removed from listing or deregistered2 occurrences · usually a matured note or preferred class, not the common shares
- 2008-03-19
- SEC comment-letter activity34 occurrences
- 2018-07-18
SEC EDGAR submissions index and 8-K item codes; 4.02 and 1.03 items are confirmed against the filing text.
What the company said
The company's own words from its current reports to the SEC, newest first
- Aug 3, 2026TG Therapeutics Reports Second Quarter 2026 Financial Results and Raises BRIUMVI ® Revenue Guidance.Earnings release · press release
- Jun 3, 2026On June 3, 2026, TG Therapeutics, Inc. (the “Company”) issued a press release announced positive pharmacokinetic (PK), pharmacodynamic (PD), safety, and tolerability data from its Phase 1 clinical trial evaluating a subcutaneous formulation of ublituximab (the active agent in BRIUMVI®) in patients with relapsing forms …Other event · Form 8-K
- May 27, 2026On May 27, 2026, TG Therapeutics, Inc. (the “Company”) issued a press release announcing positive topline results from the Phase 3 ENHANCE trial, a randomized, double-blind study evaluating a consolidated single infusion regimen for initiation of BRIUMVI® (ublituximab-xiiy) in adults with relapsing forms of multiple …Other event · Form 8-K
- Mar 20, 2026Entry into Material Definitive Agreement On March 18, 2026 (the “Closing Date”), the Company (the “Borrower”) entered into the first amendment agreement, dated as of the Closing Date (the “First Amendment”), by and among the Borrower, certain subsidiaries of the Borrower, as guarantors, the lenders party thereto and …Material agreement entered · Form 8-K
Quoted from SEC EDGAR filings. A current report is filed within four business days of the event it describes.
opening the record…